2. 疾患モデリングル製品 Immunology/Inflammation Autophagy Anti-infection
  3. Immunology and Inflammatory Disease Models Skin Disease Models Toll-like Receptor (TLR) Autophagy SARS-CoV HSV
  4. Psoriasis Models
  5. Imiquimod

イミキモド  (Synonyms: Imiquimod; R 837)

製品番号: HY-B0180 純度: 99.96%
COA 取扱説明書 Technical Support

Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 99011-02-6

容量 価格（税別） 在庫状況 数量
100 mg $66 在庫あり
200 mg $86 在庫あり
500 mg $151 在庫あり
1 g   お問い合わせ  
5 g   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 58 publication(s) in Google Scholar

Other Forms of Imiquimod:

イミキモド 関連抗体

Top Publications Citing Use of Products

顧客検証

Histological Imaging/Staining
Bio/Physico-chemical Assay
RT-PCR
WB

    Imiquimod purchased from MedChemExpress. Usage Cited in: Theranostics. 2023 Apr 9;13(7):2226-2240.  [Abstract]

    Representative images of lung of mice after indicated treatment. PFI: ICG-loaded PF127 hydrogel, PFIR: ropivacaine-loaded PFI hydrogel, PFIM: imiquimod-loaded PFI hydrogel, PFIRM: imiquimod (3 mg) and ropivacaine co-loaded PFI hydrogel.

    Imiquimod purchased from MedChemExpress. Usage Cited in: Theranostics. 2023 Apr 9;13(7):2226-2240.  [Abstract]

    1. Cumulative release profile of ICG and Imiquimod (3 mg) from PFIRM with or without laser irradiation at 1.2 W/cm2 for 5 min. The absorbance of IMQ and ICG were measured at 320 and 800 nm, respectively, using a Micro UV-Vis Spectrophotometer (LIFEREAL, FC-1100). The assay was repeated three times.

    Imiquimod purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2022 May 14;20(1):228.  [Abstract]

    TEM image and magnified TEM Image of Zr-TCPP(TPP)/R837@M nanoparticles, scale bar: 200 nm.

    Imiquimod purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2022 May 14;20(1):228.  [Abstract]

    XPS spectra of Zr-TCPP(TPP)/R837@M.

    Imiquimod purchased from MedChemExpress. Usage Cited in: MedComm (2020). 2022 Mar 4;3(1):e120.

    H&E staining of back skin sections of sham‐ or IMQ‐treated SHP2N KO and WT mice, scale bar = 200 μm.

    Imiquimod purchased from MedChemExpress. Usage Cited in: MedComm (2020). 2022 Mar 4;3(1):e120.

    IMQ (10 μM, 2 h) treatment significantly increased the proportion of neutrophils in immune cells, while SHP099 treatment significantly decreased it.

    Imiquimod purchased from MedChemExpress. Usage Cited in: MedComm (2020). 2022 Mar 4;3(1):e120.

    Results showed that neutrophil infiltration occurred in the skin tissues after IMQ (10 μM, 2 h) treatment, and SHP099 significantly reversed this phenomenon.

    Imiquimod purchased from MedChemExpress. Usage Cited in: Cell Rep. 2021 Feb 2;34(5):108724.  [Abstract]

    Primary intestinal NFs were exposed to TLR agonists and IL-1 for 12 h, and OPN mRNA was measured using qPCR analysis. The results were normalized to β-actin. ∗p < 0.05. TLR agonists were used at the following concentrations: TLR1/2 agonist (Pam3CSK4), 100 ng/mL; TLR4 agonist (LPS), 1 μg/mL; TLR7 agonist (Imiquimod; HY-B0180), 100 ng/mL; TLR8 agonist (Motolimod; HY-13773), 250 ng/mL; and IL-1, 5 ng/ml.

    Imiquimod purchased from MedChemExpress. Usage Cited in: Nat Commun. 2016 May 25;7:11724.  [Abstract]

    Freshly prepared splenic B cells are left unstimulated (lanes 1 and 4), or stimulated by 10 μg/mL αIgM for 6 or 24 h (lanes 2 and 3), or by 1 μg/mL IMQ for 6, 24, 48 and 72 h (lanes 5-8), or by αIgM and IMQ for 24 or 48 h (lanes 9+10), respectively.

    Toll-like Receptor (TLR) アイソフォーム固有の製品をすべて表示:

    すべてのアイソフォームを表示
    TLR3 TLR8 TLR9 TLR2 TLR4 TLR7 TLR1 TLR6

    HSV アイソフォーム固有の製品をすべて表示:

    すべてのアイソフォームを表示
    HSV-1 HSV-2 HSV

    • 生物活性

    • 純度とドキュメンテーション

    • 参考文献

    • カスタマーレビュー

    製品説明

    Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19[1][2].

    IC50 & Target[1][3]

    TLR7

     

    HSV-1

     

    Cellular Effect
    Cell Line Type Value Description References
    A-375 IC50
    70.3 μM
    Compound: imiquimod
    Cytotoxicity against human A375 cells after 96 hrs by MTT assay
    Cytotoxicity against human A375 cells after 96 hrs by MTT assay
    		[PMID: 18513976]
    A-375 IC50
    70.3 μM
    Compound: Imiquimod
    Cytotoxicity against human A375 cells after 96 hrs by MTT assay
    Cytotoxicity against human A375 cells after 96 hrs by MTT assay
    		[PMID: 19278757]
    HEK293 EC50
    >270 μM
    Compound: 1
    Agonist activity at human TLR8 transfected in HEK cells assessed as NFkappaB induction after 24 hrs by specific secreted alkaline phosphatase gene assay
    Agonist activity at human TLR8 transfected in HEK cells assessed as NFkappaB induction after 24 hrs by specific secreted alkaline phosphatase gene assay
    		[PMID: 22837811]
    HEK293 EC50
    10.7 μM
    Compound: 1
    Agonist activity at human TLR-7 expressed in HEK293 cells after 24 hrs by SEAP reporter gene assay
    Agonist activity at human TLR-7 expressed in HEK293 cells after 24 hrs by SEAP reporter gene assay
    		[PMID: 24383475]
    HEK293 EC50
    12.1 μM
    Compound: 1
    Agonist activity at human TLR7 transfected in HEK cells assessed as NFkappaB induction after 24 hrs by specific secreted alkaline phosphatase gene assay
    Agonist activity at human TLR7 transfected in HEK cells assessed as NFkappaB induction after 24 hrs by specific secreted alkaline phosphatase gene assay
    		[PMID: 22837811]
    HEK293 EC50
    2.12 μM
    Compound: 1
    Agonist activity at human TLR7 expressed in NF-kappaB-stimulated HEK293 cells assessed as induction of secreted alkaline phosphatase expression by reporter gene assay
    Agonist activity at human TLR7 expressed in NF-kappaB-stimulated HEK293 cells assessed as induction of secreted alkaline phosphatase expression by reporter gene assay
    		[PMID: 20481492]
    HEK293 EC50
    6.2 μM
    Compound: 1
    Agonist activity at human TLR7 in HEK293 cells cotransfected with SEAP reporter gene assessed as activity of SEAP incubated for 24 hrs by quanti-blue staining based SEAP reporter gene assay
    Agonist activity at human TLR7 in HEK293 cells cotransfected with SEAP reporter gene assessed as activity of SEAP incubated for 24 hrs by quanti-blue staining based SEAP reporter gene assay
    		[PMID: 31247373]
    LS174T IC50
    34.4 μM
    Compound: imiquimod
    Cytotoxicity against human LS174T cells after 96 hrs by MTT assay
    Cytotoxicity against human LS174T cells after 96 hrs by MTT assay
    		[PMID: 18513976]
    MCF7 IC50
    145 μM
    Compound: imiquimod
    Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay
    		[PMID: 18513976]
    Raji IC50
    139 μM
    Compound: imiquimod
    Cytotoxicity against human Raji cells after 96 hrs by MTT assay
    Cytotoxicity against human Raji cells after 96 hrs by MTT assay
    		[PMID: 18513976]
    体内実験

    Note:
    Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

    Imiquimod (IMQ) can be used to induce psoriasis models[5].

    Induction of psoriasis Model[5]
    Background
    Lmiquimod (IMQ) induces inflamed scaly skin lesions resembling plaque-type psoriasis. IMQ induces epidermal expression of IL-23, IL-17A, and IL-17F, as well as an increase in splenic Th17 cells.
    Specific Modeling Methods
    Mice: BALB/c • male • 8-week-old
    Administration: 3.125 mg/day • skin • 6 days
    Note
    IMQ cream preparation [7]:
    (1) Prepare BM of lipids
    STA and OA were melted at 75 °C followed by the addition of IMQ (3.5% of the BM, w/w) under continuous stirring.
    Polysorbate 80 and stearoyl polyoxyl-32 glycerides at a 50:50 ratio were dispersed in water heated separately to 75 °C and added to the BM phase under continuous stirring.
    (2) Prepare nanostructured lipid carriers (NLCs)
    The mixture was then subjected to high-shear homogenization followed by ultrasonication.
    The mixture was then rapidly cooled in an ice bath to allow the formation of NLCs.
    Modeling Indicators
    Behavior Observation: Induced the back skin of the mice started to display signs of erythema, scaling, and thickening.
    Resulted in hyperproliferative keratinocytes and a disturbed epidermal differentiation (parakeratosis).

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: BALB/c mice (8-11 week) [5]
    Dosage: 3.125 mg/day, 6 day
    Administration: skin
    Result: Induced the back skin of the mice started to display signs of erythema, scaling, and thickening.
    Resulted in hyperproliferative keratinocytes and a disturbed epidermal differentiation (parakeratosis).
    分子量

    240.30

    分子式

    C14H16N4
    CAS 番号
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    NC1=NC2=CC=CC=C2C3=C1N=CN3CC(C)C
    輸送条件

    Room temperature in continental US; may vary elsewhere.
    保管条件
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    溶剤 & 溶解度
    体外: 

    DMSO : 3.28 mg/mL (13.65 mM; ultrasonic and warming and adjust pH to 7 with 1 M HCl and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : 2.64 mg/mL (10.99 mM; ultrasonic and adjust pH to 2 with HCl)

    Methanol : < 1 mg/mL (insoluble)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 4.1615 mL 20.8073 mL 41.6146 mL
    5 mM 0.8323 mL 4.1615 mL 8.3229 mL
    10 mM 0.4161 mL 2.0807 mL 4.1615 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始）

    C1

    ×
    体積 （開始）

    V1

    =
    濃度 （終了）

    C2

    ×
    体積 （終了）

    V2

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    純度とドキュメンテーション

    純度: 99.96%

    COA (256 KB) LCMS (120 KB)

    取扱説明書 (2659 KB)
    参考文献

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    H2O / DMSO 1 mM 4.1615 mL 20.8073 mL 41.6146 mL 104.0366 mL
    5 mM 0.8323 mL 4.1615 mL 8.3229 mL 20.8073 mL
    10 mM 0.4161 mL 2.0807 mL 4.1615 mL 10.4037 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Imiquimod Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質量   濃度   体積   分子量 *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Imiquimod99011-02-6R 837R837R-837Toll-like Receptor (TLR)AutophagySARS-CoVHSVSARS coronavirusHerpes simplex virushumanpapillomaviruswartsmolluscumcontagiosumactinickeratosisbasal ,cellcarcinomasquamouscellBowen'sdiseasenongenitalinfectionvulvarintraepithelialneoplasiaInhibitorinhibitorinhibit

    最近チェックした製品:

    オンラインお問い合わせ

    Your information is safe with us. * Required Fields.

    製品名

    		  

    カスタマ需要量 *

    お名前 *

    		 

    タイトル

    メールアドレス *

    		 

    電話番号 *

    デパートメント

    		 

    組纖名 *

    市区町村

    都道府県

    国或いは地域 *

    		      

    必ず会社名を記載ください。個人への返信は行いません。

    備考

    バルクお問い合わせ

    Inquiry Information

    製品名:
    Imiquimod
    製品番号:
    HY-B0180
    数量:
    MCE 日本正規代理店:

    カスタマーレビュー

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    製品名

    		  

    Lot #

    お名前 *

    		 

    メールアドレス *

    電話番号 *

    		 

    部門 *

    組纖名 *

    		 

    国或いは地域 *

    備考

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.